Benjamin Halladay is CFO at Esperion Therapeutics, Inc. (ESPR). They have made 11 open-market trades across 1 company since 2024, most recently 2026-06-17.
CIK 0001953943
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 11 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ESPR | 702,829 | $2.2M |
Shares reported on the most recent Form 4, priced at the 2026-06-18 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ESPR | SELL | 2026-06-17 | 2026-06-18 | $3.16 | $34K | +0.2% | N/A | N/A |
| ESPR | SELL | 2026-03-17 | 2026-03-18 | $2.71 | $35K | +5.2% | -18.6% | +26.2% |
| ESPR | SELL | 2025-12-17 | 2025-12-18 | $3.67 | $27K | -2.1% | -23.5% | -33.7% |
| ESPR | SELL | 2025-09-17 | 2025-09-18 | $2.81 | $20K | -6.4% | -0.4% | +29.0% |
| ESPR | SELL | 2025-07-17 | 2025-07-18 | $1.12 | $12 | +19.5% | +78.0% | +124.6% |
| ESPR | SELL | 2025-06-17 | 2025-06-18 | $1.15 | $8K | -9.1% | +6.4% | +151.8% |
| ESPR | SELL | 2025-04-17 | 2025-04-21 | $0.96 | $8 | +11.8% | -3.1% | +30.7% |
| ESPR | SELL | 2025-03-18 | 2025-03-19 | $1.48 | $5K | -11.1% | -47.4% | -32.7% |
| ESPR | SELL | 2025-02-19 | 2025-02-20 | $1.86 | $20 | -5.9% | -7.4% | -54.6% |
| ESPR | SELL | 2025-01-17 | 2025-01-21 | $2.27 | $20 | -17.1% | -14.4% | -60.6% |
| ESPR | SELL | 2024-12-17 | 2024-12-18 | $2.42 | $8K | +0.5% | +0.9% | -27.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.